Why is Concord Biotech falling/rising?

As of 24-Sep, Concord Biotech Ltd is currently priced at 1,627.00, reflecting a rise of 5.05 (0.31%). The stock has shown a positive movement today, having outperformed its sector by 0.76% and gaining for the last two consecutive days, with a total increase of 0.36% during this period. It opened with a notable gain of 3.26% and reached an intraday high of Rs 1,674.85. However, despite this short-term gain, the stock has experienced significant declines over the past month and year, with returns of -8.17% and -27.04%, respectively. The company demonstrates high management efficiency with a return on equity (ROE) of 19.76% and a low debt-to-equity ratio, but it faces challenges such as a substantial drop in profit before tax and net sales, indicating poor long-term growth prospects. Additionally, the stock's valuation appears expensive relative to its peers, contributing to a bearish outlook.
In the broader market context, Concord Biotech's recent performance contrasts with the benchmark, as it has outperformed the Sensex by 0.62% in the short term, although it has underperformed over longer periods, including a -26.38% year-to-date return compared to the Sensex's +4.58%. The decline in institutional investor participation, with a decrease in their stake by -0.54%, further underscores the stock's struggles, as these investors typically have more resources to assess company fundamentals. Overall, while the stock has shown a slight uptick recently, its long-term performance and declining investor interest suggest ongoing challenges ahead.